IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer

David B. Landau, Laura Hughes, Angela Baker, Andrew T. Bates, Michael C. Bayne, Nicholas Counsell, Angel Garcia-Alonso, Susan V. Harden, Jonathan D. Hicks, Simon R. Hughes, Marianne C. Illsley, Iftekhar Khan, Virginia Laurence, Zafar Malik, Helen Mayles, William Philip M. Mayles, Elizabeth Miles, Nazia Mohammed, Yenting Ngai, Emma ParsonsJames Spicer, Paula Wells, Dean Wilkinson, John D. Fenwick

Research output: Contribution to journalArticleResearchpeer-review

37 Citations (Scopus)

Abstract

Purpose To report toxicity and early survival data for IDEAL-CRT, a trial of dose-escalated concurrent chemoradiotherapy (CRT) for non-small cell lung cancer. Patients and Methods Patients received tumor doses of 63 to 73 Gy in 30 once-daily fractions over 6 weeks with 2 concurrent cycles of cisplatin and vinorelbine. They were assigned to 1 of 2 groups according to esophageal dose. In group 1, tumor doses were determined by an experimental constraint on maximum esophageal dose, which was escalated following a 6 + 6 design from 65 Gy through 68 Gy to 71 Gy, allowing an esophageal maximum tolerated dose to be determined from early and late toxicities. Tumor doses for group 2 patients were determined by other tissue constraints, often lung. Overall survival, progression-free survival, tumor response, and toxicity were evaluated for both groups combined. Results Eight centers recruited 84 patients: 13, 12, and 10, respectively, in the 65-Gy, 68-Gy, and 71-Gy cohorts of group 1; and 49 in group 2. The mean prescribed tumor dose was 67.7 Gy. Five grade 3 esophagitis and 3 grade 3 pneumonitis events were observed across both groups. After 1 fatal esophageal perforation in the 71-Gy cohort, 68 Gy was declared the esophageal maximum tolerated dose. With a median follow-up of 35 months, median overall survival was 36.9 months, and overall survival and progression-free survival were 87.8% and 72.0%, respectively, at 1 year and 68.0% and 48.5% at 2 years. Conclusions IDEAL-CRT achieved significant treatment intensification with acceptable toxicity and promising survival. The isotoxic design allowed the esophageal maximum tolerated dose to be identified from relatively few patients.

Original languageEnglish
Pages (from-to)1367-1377
Number of pages11
JournalInternational Journal of Radiation Oncology Biology Physics
Volume95
Issue number5
DOIs
Publication statusPublished - 1 Aug 2016
Externally publishedYes

Cite this